{"entity":{"id":"cd47-blockade","kind":"technology","name":"CD47 and SIRP-alpha blockade","aka":[],"tldr":"Drugs that remove the 'don't eat me' signal cancer cells show to macrophages, so the immune system's scavenger cells can engulf them; the lead programme was halted for safety.","summary":"CD47 on tumour cells binds SIRP-alpha on macrophages and stops them engulfing the cell. Antibodies and fusion proteins that block the axis (magrolimab, evorpacept and others) boost antibody-dependent phagocytosis, especially with rituximab or azacitidine. Magrolimab's phase 3 programme in myelodysplastic syndromes and acute myeloid leukaemia was stopped in 2024 after excess deaths, but SIRP-alpha-directed agents and bispecifics continue in lymphoma and solid tumours.","status":"phase-2","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/CD47","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/CD47"}],"tags":[],"related":[],"cancers":["mds","aml","dlbcl"],"sections":["immunotherapy"],"technologies":[],"targets":["cd47"],"drugs":["magrolimab","evorpacept"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Blocking CD47 or SIRP-alpha removes the inhibitory signal so macrophages phagocytose opsonised tumour cells; agents are engineered to spare red cells, which also express CD47.","strengths":["Engages macrophages, a different arm from T-cell checkpoints","Synergy with therapeutic antibodies"],"limitations":["Anaemia from red cell CD47","Magrolimab programme stopped for safety","No approval yet"]},"route":"/technologies/cd47-blockade/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"},{"id":"mds-higher-risk","kind":"cancer","name":"Higher-risk myelodysplastic syndromes","route":"/cancers/mds-higher-risk/"},{"id":"mds","kind":"cancer","name":"Myelodysplastic syndromes / neoplasms (MDS)","route":"/cancers/mds/"},{"id":"aml-secondary","kind":"cancer","name":"Secondary and therapy-related acute myeloid leukaemia","route":"/cancers/aml-secondary/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"target":[{"id":"cd24","kind":"target","name":"CD24","route":"/targets/cd24/"},{"id":"cd47","kind":"target","name":"CD47","route":"/targets/cd47/"}],"drug":[{"id":"evorpacept","kind":"drug","name":"Evorpacept","route":"/drugs/evorpacept/"},{"id":"magrolimab","kind":"drug","name":"Magrolimab","route":"/drugs/magrolimab/"}],"technology":[{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"}],"trial":[{"id":"aspen-06","kind":"trial","name":"A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)","route":"/trials/aspen-06/"},{"id":"nct07007559","kind":"trial","name":"ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer","route":"/trials/nct07007559/"},{"id":"nct04675333","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)","route":"/trials/nct04675333/"},{"id":"nct04675294","kind":"trial","name":"Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)","route":"/trials/nct04675294/"}]}}